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Abstract
Background: Maturity onset diabetes of the young (MODY) is an autosomal dominant form of non–insulin-
dependent diabetes mellitus caused by mutations in at least 13 different genes. The hepatocyte nuclear factor
(HNF)-1α gene is affected in the most common form (HNF1A-MODY [MODY3]).
Case presentation: We describe the co-inheritance of a novel heterozygous missense mutation c.1761C > G
(p.Pro588Ala) with a novel complex deletion insertion mutation (c.1765_1766delinsGCCCGfs86*) in the HNF-1α gene
among affected members of one family. Both mutations were present in the affected patients and neither was
present in unaffected family members. The family had not only inheritance of MODY but also increased
susceptibility to type 2 diabetes. Therefore one family member had classical type 2 diabetes including metabolic
syndrome aggravated by a genetic predisposition in the form of HNF1A-MODY.
Conclusion: The presence of common type 2 diabetes features should not detract from the possibility of MODY in
patients with a striking autosomal-dominant family history.
Keywords: Maturity-onset diabetes of the young, HNF1A-MODY, HNF-1α, Metabolic syndrome, Metabolic challenge,
Phenotype variety
Background
Maturity onset diabetes of the young (MODY) com-
prises a group of clinically and genetically heterogeneous
familial disorders with a clinical appearance similar to
non–insulin-dependent type 2 diabetes that is caused by
mutations in at least 13 different genes (MODY1 to
MODY13) [1, 2]. MODY is characterized by autosomal
dominant inheritance and early onset diabetes, but
otherwise the phenotype appears to be heterogeneous
[1–3]. HNF1A-MODY (MODY3) is the most common
form of the disorder in white populations and is caused
by mutations and, rarely, deletions affecting HNF-1α, a
transcription factor that functions in the transcriptional
network necessary for liver as well as pancreatic β-cell
development and function [4]. HNF1A-MODY is a clin-
ically progressive phenotype with progressive hypergly-
cemia, glycosuria, and decreased renal function or
microvascular complications, which can be reduced sub-
stantially by early treatment [1–3, 5]. We report siblings
with novel HNF1A-MODY mutations but with different
clinical manifestations. This finding may be due to an
additional maternal predisposition for type 2 diabetes,
which has aggravated the genetic susceptibility burden
for the diabetes phenotype in one of the siblings.
Case presentation
The index patient (female, age 43 years at examination)
and five further family members agreed to undertake
molecular analyses. The proband and three family mem-
bers were analyzed for serum metabolic parameters; two
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patients (the index female patient and her male sibling)
agreed to ultrasound examination, an interventional oral
glucose tolerance test (oGTT) and lipid tolerance test-
ing. For ethical reasons family members age <18 years
and individuals with further overt clinical symptoms did
not undergo interventional investigations. All interven-
tions were performed at the Asklepios Clinik St. Georg
(Hamburg, Germany). Written informed consent was
obtained from all participants (parents provided in-
formed consent on behalf of subjects age <18 years).
The study protocol and procedure were approved by the
parents of the participating children and the ethical
committee of the University of Hamburg. The study was
conducted according to principles laid out in the Declar-
ation of Helsinki.
Determination of metabolic parameters
Blood and serum samples were collected according to
standard protocols. Automated standard systems for
measuring clinical variables, including insulin, glucose,
hemoglobin A1c, cholesterol (including high-density and
low-density lipoprotein) and triglycerides, were used.
Standard surrogate indexes were calculated from fasting
blood glucose and plasma insulin concentrations as
follows: quantitative insulin sensitivity check index
QUICKI = 1/(log(I0) + log(G0)), where I0 is fasting insulin
(μU/ml) and G0 is fasting glucose (mg/dl); and
homeostatic model assessment of insulin resistance
HOMA-IR = (G0 * I0)/22.5, with fasting glucose expressed
as mmol/l and fasting insulin expressed as μU/ml. Cre-
atinine, albumin and glucose concentrations were deter-
mined from urine samples. To exclude the presence of
type 1 diabetes or latent autoimmune diabetes of adults,
measurement of antibodies against insulin, GAD, thyro-
sine phosphatase (IA2), and islet cells (ICA) were deter-
mined. Blood pressure, ophthalmoscopy and angiography
of lower extremities were determined in 3 probands.
Molecular analyses
Genomic DNA was extracted from whole blood using the
blood extraction kit (Qiagen, Hilden, Germany). The tar-
geted resequencing approach of glucokinase, HNF-1α,
HNF-1β, HNF-4α, IPF-1/PDX-1 and NeuroD1/β2 including
all splice variants and related promoter areas corresponding
to the molecular basis of the most prevalent MODY1 to
MODY6 have been reported [6]. Nucleotide numbering of
HNF-1α was given according to NM_000545.5.
Metabolic testing
To determine fat tolerance, a breakfast with a total en-
ergy content of 1080 kcal (47 % fat, 40 % carbohydrates
and 13 % proteins) was served after a 10-h fasting period
under current medication. Blood was drawn before the
meal (0 min) and 120 min and 240 min after food
consumption [7]. To test oGTT, blood samples were
drawn before (0 min) and 60 min and 120 min after a
75 mg oral glucose load under current antidiabetic
therapy.
Results
The index patient reported early onset of diabetes at age
25 years. No type 1 diabetes specific antibody pattern was
detected, but proteinuria and recurrent nephrolithiasis
were reported. In the index patient, diabetes had been di-
agnosed 3 years before the first pregnancy and she devel-
oped obstetric diabetic complications during all of her
four pregnancies, which were treated with insulin. Two
pregnancies were successful, but both newborns devel-
oped reversible jaundice, macrosomia and hypoglycemia
within the first 2 weeks.
Examination of the family history revealed that her
brother also showed early onset diabetes (at 16 years),
whereas her parents were both diagnosed as diabetic in
routine health screens. The father was diagnosed at the
age of 38 years without microvascular complications, in-
cluding a stable HbA1c of <7.0 % whereas the mother
had typical late onset diabetes diagnosed at age 56 years.
Thus the family history indicated type 2 diabetes at the
maternal site and diabetes with autosomal heritage and
early onset at the paternal site. The positive family his-
tory, especially with clinical manifestation at a young age
with lack of diabetes-related autoantibodies, is a feature
typical of MODY. In accordance with this finding, we
identified a novel heterozygous missense mutation
c.1761C > G (p.Pro588Ala) in the index patient. More-
over, a novel complex deletion insertion mutation at
c.1765_1766delinsGCCCGfs86*, resulting in a frameshift
in exon 9 of the HNF-1α gene (Fig. 1a), was detected.
Both mutations were inherited together and co-
segregated with an early onset diabetes phenotype in the
family, indicating the genotype–phenotype association
over three generations. One child of the family was a
carrier of the mutations and diagnosed diabetic at the
age of 12 with blood glucose 147 mg/dl and HbA1c
6,9 % (Fig. 1b).
Although the mutations were present in both over-
weight siblings, their metabolic phenotypes differed
(Table 1). The index patient (body mass index 27 kg/m2)
showed elevated fasting glucose and insulin concentra-
tions, increased HbA1c, moderately elevated triglyceride
concentrations and dyslipidemia. Ophthalmoscopy, angi-
ography of the lower extremities and ultrasound examin-
ation of the abdomen were performed. No microvascular
complications were identified, but low-grade hepatic
steatosis and an unaffected pancreas were determined.
The brother also showed elevated fasting blood glucose
and proteinuria, but no type 1 diabetes-specific anti-
bodies or microvascular complications were detectable.
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In contrast to the index patient, fasting insulin was nor-
mal and HbA1c was significantly increased. Further-
more, features of the metabolic syndrome, including
obesity (body mass index 30 kg/m2) and dyslipidemia,
were more pronounced. Ultrasound examination indi-
cated severe homogenous steatosis and liver enlarge-
ment with low-grade splenomegaly and a lipomatous
pancreas. The patient was also a tobacco smoker, a fur-
ther risk factor.
To further characterize potential differences in the meta-
bolic response, the siblings were challenged with oral glu-
cose and separately with a lipid-rich meal (Tables 2 and 3).
The index patient showed a diabetes-specific pattern in all
variables analyzed in the oGTT. The brother was in the
near-normal range except for his triglyceride concentration.
As the fasting triglyceride concentration was pathologically
high, the values showed only an average decrease to
4.5 mmol/l under glucose load. The lipid profile was aggra-
vated under lipid tolerance tests. Following lipid load,
glucose concentrations in the siblings are nearly identical
but were elevated compared with the normal range
[8–10]. Most strikingly, in the brother, during the
lipid tolerance test fasting triglycerides increased from
8.5 mmol/l to >11.4 mmol/l and declined to
10.1 mmol/l within 2 h. Again, the vast increase in
triglyceride concentrations in the lipid tolerance test
was not observed in the index patient.
Conclusions
We identified two sequence variations in the HNF-1α gene
in siblings with divergent clinical manifestations of type 2
diabetes, metabolic syndrome and HNF1A-MODY muta-
tions. One is a heterozygous mutation of c.1761C >G
(p.Pro588Ala). The other is a complex deletion inser-
tion mutation at c.1765_1766delinsGCCCGfs86* altering
p.Thr589Ser and inserting a further p.P589 + 1 in exon 9
but not affecting the splicing site directly. The mutations
identified were not reported in the exome sequencing-based
database of human variation consisting of approximately
60,000 individual samples (http://exac.broadinstitute.org/
gene/ENSG00000135100). A mutation of 1785C >T
(p.Pro588Ser) has been reported in a previous study of
MODY families [11], and Colclough et al. [12] observed a
frameshift deletion mutation c.1765_1766delCA at the
identical site of the mutation identified here. Al-
though both previous reports did not describe the af-
fected families [11, 12], these observations indicate
the importance of this area of the HNF-1α gene as a
mutation hotspot. This, alongside the dominant inherit-
ance and the co-segregation with diabetes phenotype,
Fig. 1 Co-segregation of the mutations and key clinical characteristics. a A heterozygous mutation (c.1761C > G (p.Pro588Ala)) and a complex
deletion insertion mutation (c.1765_1766delinsGCCCGfs86*) in exon 9 of the HNF-1α gene were identified by direct sequencing (upper panel:
control, middle patient forward strand, below: patient reverse strand). Horizontal arrows indicate direction of sequencing; vertical arrows indicate
sequence alterations. b Co-segregation of the HNF-1α mutations in the family. The genetic status, age of onset of diabetes, current therapy and
date of birth are indicated. Numbers indicate the index patient and the brother. (Black symbol: early onset diabetes phenotype; grey symbol: late
onset type 2 diabetes NM: heterozygous mutation present; NN: no mutation; INS: insulin; OHA: oral hypoglycemic agents; SU: sulfonylurea). In
detail, at time of investigation the medication was as follows: index patient (insulin, angiotensin-converting-enzyme inhibitors), brother (glinide),
daughter (metformin), father (insulin, statin, glibenclamide), and mother (metformin, glibenclamide, statin, angiotensin-converting-enzyme inhibitors)
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stresses the hypothesis that the mutation causes the
MODY phenotype in the family described here.
HNF-1α is composed of three functional domains, and
three isoforms are generated by alternative splicing, with
different transcriptional properties and tissue expression
patterns [13, 14]. Mechanistically both mutations affect
the transactivation domain of the HNF-1α isoform A
with the isoform specific exons 8 to 10 of the transacti-
vation domain, which is mainly expressed in the fetal
pancreas [14]. An older age at onset was observed in
HNF1A-MODY patients carrying a HNF-1α missense
mutation affecting specifically the HNF-1α (A) isoform
(10B) [11]. Interestingly, in vitro studies indicated that
truncation of exon 10 decreases transcriptional activa-
tion by HNF-1α by approximately 50 % [15]. Although
the splicing site is not affected directly, as a functional
consequence after splicing the reading frame of the en-
tire exon 10 is shifted to generate an 85 AA sequence
without any homology to known protein sequences. As
the HNF-1α isoform A is mainly expressed in the
fetal pancreas [14], one may speculate that identified
mutations interfere with susceptibility to type 2 dia-
betes on the level of pancreas functionality or
maturation.
MODY in adults is often clinically misdiagnosed as type
1 or type 2 diabetes [3]. Therefore it is tempting to specu-
late that HNF1A-MODY is under-diagnosed in the ‘sink’
of common type 2 diabetes. HNF1A-MODY is a clinically
progressive phenotype with hyperglycemia, glycosuria,
and decreased renal function or microvascular compli-
cations, and usual associations with microvascular
and macrovascular complications commensurate with
glycemic control [1, 2, 16]. In our family, HNF1A-
MODY presents clinically as diabetes without dyslip-
idemia, as reflected by the index patient. In contrast,
HNF1A-MODY was aggravated in the brother by
classical insulin resistant type 2 diabetes or features






Sex – Female Male
Age at examination, years – 43 39
Weight (kg) – 69 93
Height (cm) – 159 177
Waist circumference (cm) - 94 108




Fasting glucose (mmol/l) 4.1–6.1 12.7 12.8
Hemoglobin A1c (%) 4.8–5.9 7.4 8.9
Triglycerides (mmol/l) <1.7 2.2 6.9







Urea–albumin (mg/l) <20 22 73
Creatinine (mg/l) 5.3-8.9 3.5 6.2




Islet cell antibodies (JDF U) <5 1.3 1.3
Islet antigen 2 antibodies (mlU/ml) <70 <25 <1.3
C-peptide (nmol/l) 0.3–1.7 0.4 0.7
Insulin (pmol/l) 18.1–173.3 247.2* 76.4
Lipase (mmol*s/l) <100 46.7 145
Data are shown as mean ± S.D. standard deviation. *: p-values < 0.05 (unpaired
t-test with the assumption of normal distributed parameters) were accepted
as significant
Table 2 Results from the oral glucose tolerance test in the
siblingsa
Normal rangeb Patient 1 (index) Patient 2
Glucose (mmol/l)
0 min <6.1 13.5 11.5
60 min 21.0 21.0
120 min <7.8 22.2 16.0
180 min 15.8 11.7
Triglyceride (mmol/l) <1.71
0 min 3.2 6.1
60 min 3.5 4.9
120 min 3.5 4.4
180 min 3.7 4.2
Total cholesterol (mmol/l) <5.2
0 min 6.6 6.5
60 min 6.4 5.7
120 min 6.4 5.7
180 min 6.9 6.0
C-peptide (nmol/l) 0.27–1.72
0 min 0.4 0.7
60 min 0.8 1.0
120 min 0.6 1.2
180 min 0.7 0.7
Insulin (pmol/l) 18.1–173.6
0 min 247.2 76.4
60 min 209.7 84.0
120 min 184.0 140.3
180 min 139.3 36.8
aClinical biochemical parameters of the siblings in an oral glucose tolerance
test (75 mg oral glucose load) under current medication (patient 1: insulin;
angiotensin-converting-enzyme inhibitors; patient 2 glinide; no lipid lowering
therapy). bMean values reported in healthy populations, na: not available
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of metabolic syndrome indicated by dyslipidemia with
severe hypertriglyceridemia and hepatic steatosis.
Family history and triglyceride concentrations are of
special importance in the differentiation of insulin-
resistant type 2 diabetes and HNF1A-MODY. In general,
type 2 diabetes is characterized by significantly higher
triglyceride values and lower high-density lipoprotein
cholesterol compared with HNF1A-MODY or non-
diabetics, with a high-density lipoprotein cholesterol >
1.12 mmol/l discriminates HNF1A-MODY from type 2
diabetes with 75 % sensitivity and 64 % specificity [17].
On the other hand increased circulating serum lipids
are also a combinatory risk factor to various metabolic
diseases such as type 2 diabetes. To investigate whether
circulating lipids are of special importance in such com-
bined diabetes types, we challenged the affected siblings
with lipid and glucose tolerance tests, but gained no fur-
ther insight beside the present basal clinical features of
type 2 diabetes or a more severe insulin-resistant pheno-
type in the affected brother. Therefore these investigations
did not shed light on further therapeutic approaches ex-
cept therapy for type 2 diabetes.
In our patients, one possible hypothesis for the differ-
ences in lipid metabolism observed might be the differing
distribution of the maternal genetic predisposition for type
2 diabetes (e.g. in heterozygous states). In combination
with the genetic predisposition of the HNF1A-MODY-
relevant mutations, this resulted in an exponential meta-
bolic risk, which may be triggered by lifestyle factors.
Although in cases with occurrence of type 2 diabetes and
HNF1A-MODY-relevant mutations such as this, treat-
ment of type 2 diabetes is the major clinical aim, therapy
should be optimized according to the patients’ genetic
profile because a MODY-relevant mutation alters the
therapeutic needs. Mutations affecting HNF-1α transcrip-
tional activity interfere with activation of cellular HNF-1α
targets, which has been shown to decrease the uptake of
sulfonylurea, resulting in increased circulating levels [18].
Therefore patients with HNF1A-MODY have been shown
to be hypersensitive to sulfonylurea therapy [19, 20],
which makes sulfonylurea the therapy of choice. Never-
theless, tight dose control may be needed for the individ-
ual patient. Taken together, the presence of common type
2 diabetes features should not detract from the possibility
of MODY in patients with a striking autosomal dominant
family history, in order to optimize the individual therapy.
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